Eyepoint Pharmaceuticals’ (EYPT) “Hold” Rating Reiterated at Laidlaw

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “hold” rating reaffirmed by research analysts at Laidlaw in a note issued to investors on Tuesday, Benzinga reports.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings upgraded shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Chardan Capital downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Tuesday, August 18th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Guggenheim downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Finally, Royal Bank Of Canada cut their price objective on Eyepoint Pharmaceuticals to $1.00 and set a “sector perform” rating for the company in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $21.85.

Eyepoint Pharmaceuticals Stock Up 2.3%

EYPT stock traded up $0.01 during midday trading on Tuesday, hitting $0.45. The company’s stock had a trading volume of 30,958,341 shares, compared to its average volume of 3,191,551. Eyepoint Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $19.11. The firm has a market capitalization of $38.79 million, a price-to-earnings ratio of -0.12 and a beta of 1.67. The company has a 50 day moving average of $4.77 and a two-hundred day moving average of $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The company had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. On average, analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.

Institutional Trading of Eyepoint Pharmaceuticals

Several hedge funds have recently made changes to their positions in EYPT. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at about $29,000. Integrated Wealth Concepts LLC purchased a new position in Eyepoint Pharmaceuticals in the second quarter worth about $72,000. Pictet Asset Management Holding SA bought a new stake in Eyepoint Pharmaceuticals during the first quarter worth approximately $141,000. Engineers Gate Manager LP bought a new stake in Eyepoint Pharmaceuticals during the second quarter worth approximately $161,000. Finally, Janney Montgomery Scott LLC increased its stake in Eyepoint Pharmaceuticals by 14.8% during the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock worth $391,000 after acquiring an additional 3,900 shares during the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada said upcoming data from EyePoint’s diabetic macular edema (DME) study could provide a catalyst after the Phase 3 LUCIA trial in wAMD missed its primary endpoint. RBC maintained a “sector perform” rating but lowered its price target to $1.00, implying substantial potential upside from current levels. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says
• Positive Sentiment: EyePoint is prioritizing its late-stage DURAVYU program in DME, a move intended to reduce spending and concentrate resources on the company’s remaining major clinical opportunity. EyePoint Announces Strategic Prioritization
• Positive Sentiment: Trading activity included unusually high call-option volume, with 7,885 calls purchased—about 69% above typical daily volume—suggesting some speculative traders are positioning for a recovery, although this is not a fundamental improvement.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.